News

Health And Pharma1h
Leucid Bio Doses First Patient in AERIAL Trial of LEU011, a Novel CAR-T Therapy for Solid Tumors
Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial of LEU011, an NKG2D-targeting CAR-T therapy for solid ...
Health And Pharma2d
Oncologists Struggle with Innovation Overload: 'The Growing Chasm in Cancer Care'
Johnson & Johnson’s Oncology Care Index reveals 73% of oncologists see a gap between new cancer treatments and clinical ...
Health And Pharma6d
Elraglusib Shows Survival Benefit in First-Line Metastatic Pancreatic Cancer Trial
In a 286-patient Phase 2 trial, elraglusib combined with gemcitabine/nab-paclitaxel achieved a statistically significant ...
Health And Pharma4d
POTOMAC Trial: Durvalumab Plus BCG Boosts Outcomes in Early-Stage Bladder Cancer
Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...
Health And Pharma6d
Enhertu Plus THP Outperforms Standard Chemotherapy in High-Risk, Early-Stage HER2+ Breast Cancer
The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...
Health And Pharma4d
FDA Announces Generative AI Strategy with First AI-Assisted Scientific Pilot to Accelerate Drug Review
For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...
healthandpharma4d
A Turning Point: Avutometinib + Defactinib Earn Accelerated FDA Approval for Rare Ovarian Cancer
The FDA granted accelerated approval to Avutometinib + Defactinib (Avmapki Fakznja Co-Pack) for KRAS-mutated recurrent low-grade serous ovarian cancer. In the Phase 2 RAMP 201 trial, the oral ...